Novo Nordisk's DegludecPlus filing ups ante in Japan basal insulin market
This article was originally published in Scrip
Novo Nordisk has filed for the approval in Japan of its combination product DegludecPlus (70% insulin degludec plus 30% fast-acting insulin aspart (NovoRapid)), for the treatment of both type 1 and 2 diabetes.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.